1 – 40 of 40
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data
2024) In Leukemia and Lymphoma(
- Contribution to journal › Article
-
Mark
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
(
- Contribution to journal › Letter
- 2023
-
Mark
Exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma– pooled analysis of three Swedish case-control studies including the sub-type hairy cell leukemia
(
- Contribution to journal › Article
-
Mark
Exploring new prognostic biomarkers in Mantle Cell Lymphoma : a comparison of the circSCORE and the MCL35 score
(
- Contribution to journal › Article
- 2021
-
Mark
Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets
(
- Contribution to journal › Article
- 2020
-
Mark
Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis
(
- Contribution to journal › Article
- 2019
-
Mark
Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML
(
- Contribution to journal › Article
-
Mark
The epidemiological trend of acute promyelocytic leukemia over past four decades : a population-based analysis
(
- Contribution to journal › Article
- 2018
-
Mark
Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations
(
- Contribution to journal › Article
- 2017
-
Mark
Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
(
- Contribution to journal › Letter
-
Mark
Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker
(
- Contribution to journal › Article
-
Mark
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
(
- Contribution to journal › Article
-
Mark
Outcome of peripheral T-cell lymphoma in first complete remission : a Danish-Swedish population-based study
(
- Contribution to journal › Article
- 2016
-
Mark
Detailed gene dose analysis reveals recurrent focal gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia
(
- Contribution to journal › Article
- 2015
-
Mark
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
(
- Contribution to journal › Article
-
Mark
F-18-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study
(
- Contribution to journal › Article
-
Mark
Joint occurrence of Merkel cell carcinoma and non-Hodgkin lymphomas in four Nordic countries
(
- Contribution to journal › Article
-
Mark
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Scientific review
- 2014
-
Mark
High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial
(
- Contribution to journal › Letter
-
Mark
Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study
(
- Contribution to journal › Article
-
Mark
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic
(
- Contribution to journal › Article
-
Mark
Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas
(
- Contribution to journal › Article
- 2013
-
Mark
Protein kinase C expression is deregulated in chronic lymphocytic leukemia
(
- Contribution to journal › Letter
- 2012
-
Mark
MyelomA Genetics International Consortium
(
- Contribution to journal › Scientific review
-
Mark
Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study
(
- Contribution to journal › Letter
-
Mark
Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
(
- Contribution to journal › Article
- 2011
-
Mark
The association of cancer and venous thrombosis: yes, Trousseau is right ... again!
(
- Contribution to journal › Debate/Note/Editorial
- 2010
-
Mark
Diversity in antibody-based approaches to non-Hodgkin lymphoma
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2008
-
Mark
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
(
- Contribution to journal › Article
- 2007
-
Mark
Establishment of a cell line from a chemotherapy resistant diffuse large B-cell lymphoma
(
- Contribution to journal › Letter
-
Mark
Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN
(
- Contribution to journal › Article
-
Mark
CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma.
(
- Contribution to journal › Article
-
Mark
A limited number of IgH-primers binding to framework region 1 is sufficient to detect the majority of mature small B-cell non-Hodgkin lymphomas on formalin-fixed paraffin-embedded tissue by PCR
(
- Contribution to journal › Article
- 2006
-
Mark
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy plus G-CSF in patients with chronic myelogenous leukemia in first chronic phase
(
- Contribution to journal › Article
-
Mark
Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1
(
- Contribution to journal › Article
- 2002
-
Mark
Exposure to pesticides as risk factor for Non-Hodgkin's lymphoma and hairy cell leukemia : Pooled analysis of two Swedish case-control studies
(
- Contribution to journal › Article
- 2001
-
Mark
Case-control study on concentrations of organohalogen compounds and titers of antibodies to Epstein-Barr virus antigens in the etiology of non-Hodgkin lymphoma
(
- Contribution to journal › Article